Use the labels in the right column to find what you want. Or you can go thru them one by one, there are only 29,380 posts. Searching is done in the search box in upper left corner. I blog on anything to do with stroke. DO NOT DO ANYTHING SUGGESTED HERE AS I AM NOT MEDICALLY TRAINED, YOUR DOCTOR IS, LISTEN TO THEM. BUT I BET THEY DON'T KNOW HOW TO GET YOU 100% RECOVERED. I DON'T EITHER BUT HAVE PLENTY OF QUESTIONS FOR YOUR DOCTOR TO ANSWER.
Thursday, January 16, 2020
New use for an old drug: The potential of colchicine in CVD
Well, did your stroke hospital do ONE DAMN THING with this earlier
research on colchicine? If not, what the fuck use is your stroke hospital? Who
specifically are they waiting for to solve stroke? Call the president
and ask when competent persons will be hired to put stroke research into
protocols.
Secondary
prevention of CVD with colchicine is a major focus for the cardiology
community, especially after recent presentations of the COLCOT and
COLCHICINE-PCI trials at the American Heart Association Scientific
Sessions in November.
Repurposing of drugs for CV applications has become more common, as
researchers have learned how the mechanisms of certain drugs may offer
benefit for various conditions.
“The revolution going on is trying to think about drugs that are
traditionally used to treat rheumatoid arthritis can now actually be
used to treat atherosclerosis. This repurposing process is really very
interesting,” Paul M. Ridker, MD, MPH, FACC, FAHA, director
of the Center for Cardiovascular Disease Prevention at Brigham and
Women’s Hospital and Eugene Braunwald Professor of Medicine at Harvard
Medical School, told Cardiology Today.
Binita Shah, MD, MS, from NYU Langone
Health, said colchicine appears to reduce vascular inflammation, but
more research is needed to determine optimal clinical use.Source: NYU Langone Health. Reprinted with permission.
Colchicine, which has been investigated for CV applications for more than a decade, is a prominent example of this trend.
In the COLCOT trial, researchers found adults with a recent MI were
less likely to experience an ischemic CV event over 2 years when
assigned 0.5 mg per day of colchicine, an anti-inflammatory medication,
compared with those assigned placebo. In addition, colchicine was
associated with a 74% reduction in stroke risk and a 50% reduction in
risk for angina hospitalization leading to revascularization. In the
COLCHICINE-PCI trial, in patients with suspected ischemic heart disease
or ACS referred for coronary angiography with possible PCI, acute
preprocedural administration of 1.8 mg of colchicine did not reduce
PCI-related myocardial injury or major adverse CV events compared with
placebo. A secondary analysis showed attenuation of the inflammatory
biomarker response.
Aruna D. Pradhan
“COLCOT demonstrated clinical efficacy of colchicine for
cardiovascular risk reduction in patients with recent myocardial
infarction,” Aruna D. Pradhan, MD, MPH, associate
physician at Brigham and Women’s Hospital and assistant professor of
medicine at Harvard Medical School, said during a discussant
presentation at the AHA Scientific Sessions. “It was a large, simple and
well-designed event-driven trial which aimed to answer one core
question. This will be a landmark study. These results provide
confirmation that inflammation management reduces cardiovascular risk,
and it was an example of successful repurposing of a broadly available
and relatively safe generic drug for a new application.”
In an interview with Cardiology Today, Jean-Claude Tardif, MD,
director of research at the Montreal Heart Institute, principal
investigator of COLCOT, said that “by repurposing well-known medications
like colchicine, we can help address the major public health issue of
subsequent CV events after an MI in a cost-effective manner, to help
patients worldwide overcome the cost barriers of their treatment.”
No comments:
Post a Comment